Prospects of vaccination in autoimmune diseases

B. L. Chiang, A. Ansari, M. Eric Gershwin

Research output: Contribution to journalArticle

Abstract

Over the past several years, intensive efforts have been directed to define the pathogenic mechanisms and explore the potential immunotherapy of autoimmune diseases. The advances of molecular genetics and cellular immunology have now permitted select experimental immunotherapy using synthetic peptides, T cell receptor idiotypes and monoclonal antibodies. There remain many obstacles for success. First, the T cell receptor usage of autoreactive T cells in human autoimmune diseases are more heterogeneous than animal models. Clearly, there may not be an oligoclonal derivation of T cells in humans with autoimmune diseases. We foresee that the following studies might contribute to further understand pathogenic mechanisms and design feasible immunotherapy: (1) detailed characterizations of self-antigen specific T cell clones; (2) definition of interactions between MHC molecules and T cell receptors at the molecular level; (3) identification and elution of relevant disease inducing self-peptides complexed with MHC molecules and (4) identification of relevant genes that predispose to autoimmunity.

Original languageEnglish (US)
Pages (from-to)181-188
Number of pages8
JournalInternational Archives of Allergy and Immunology
Volume98
Issue number3
StatePublished - 1992

Fingerprint

T-Cell Antigen Receptor
Immunotherapy
Autoimmune Diseases
Vaccination
T-Lymphocytes
Peptide T
Autoantigens
Allergy and Immunology
Autoimmunity
Molecular Biology
Animal Models
Clone Cells
Monoclonal Antibodies
Peptides
Genes

Keywords

  • Autoantibodies
  • Autoimmunity
  • Myasthenia gravis
  • New Zealand mice
  • Systemic lupus erythematosus
  • T cell receptor
  • Vaccination

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Prospects of vaccination in autoimmune diseases. / Chiang, B. L.; Ansari, A.; Gershwin, M. Eric.

In: International Archives of Allergy and Immunology, Vol. 98, No. 3, 1992, p. 181-188.

Research output: Contribution to journalArticle

@article{a84b09d9521544b5a43cb5f939ae88c6,
title = "Prospects of vaccination in autoimmune diseases",
abstract = "Over the past several years, intensive efforts have been directed to define the pathogenic mechanisms and explore the potential immunotherapy of autoimmune diseases. The advances of molecular genetics and cellular immunology have now permitted select experimental immunotherapy using synthetic peptides, T cell receptor idiotypes and monoclonal antibodies. There remain many obstacles for success. First, the T cell receptor usage of autoreactive T cells in human autoimmune diseases are more heterogeneous than animal models. Clearly, there may not be an oligoclonal derivation of T cells in humans with autoimmune diseases. We foresee that the following studies might contribute to further understand pathogenic mechanisms and design feasible immunotherapy: (1) detailed characterizations of self-antigen specific T cell clones; (2) definition of interactions between MHC molecules and T cell receptors at the molecular level; (3) identification and elution of relevant disease inducing self-peptides complexed with MHC molecules and (4) identification of relevant genes that predispose to autoimmunity.",
keywords = "Autoantibodies, Autoimmunity, Myasthenia gravis, New Zealand mice, Systemic lupus erythematosus, T cell receptor, Vaccination",
author = "Chiang, {B. L.} and A. Ansari and Gershwin, {M. Eric}",
year = "1992",
language = "English (US)",
volume = "98",
pages = "181--188",
journal = "International Archives of Allergy and Immunology",
issn = "1018-2438",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - Prospects of vaccination in autoimmune diseases

AU - Chiang, B. L.

AU - Ansari, A.

AU - Gershwin, M. Eric

PY - 1992

Y1 - 1992

N2 - Over the past several years, intensive efforts have been directed to define the pathogenic mechanisms and explore the potential immunotherapy of autoimmune diseases. The advances of molecular genetics and cellular immunology have now permitted select experimental immunotherapy using synthetic peptides, T cell receptor idiotypes and monoclonal antibodies. There remain many obstacles for success. First, the T cell receptor usage of autoreactive T cells in human autoimmune diseases are more heterogeneous than animal models. Clearly, there may not be an oligoclonal derivation of T cells in humans with autoimmune diseases. We foresee that the following studies might contribute to further understand pathogenic mechanisms and design feasible immunotherapy: (1) detailed characterizations of self-antigen specific T cell clones; (2) definition of interactions between MHC molecules and T cell receptors at the molecular level; (3) identification and elution of relevant disease inducing self-peptides complexed with MHC molecules and (4) identification of relevant genes that predispose to autoimmunity.

AB - Over the past several years, intensive efforts have been directed to define the pathogenic mechanisms and explore the potential immunotherapy of autoimmune diseases. The advances of molecular genetics and cellular immunology have now permitted select experimental immunotherapy using synthetic peptides, T cell receptor idiotypes and monoclonal antibodies. There remain many obstacles for success. First, the T cell receptor usage of autoreactive T cells in human autoimmune diseases are more heterogeneous than animal models. Clearly, there may not be an oligoclonal derivation of T cells in humans with autoimmune diseases. We foresee that the following studies might contribute to further understand pathogenic mechanisms and design feasible immunotherapy: (1) detailed characterizations of self-antigen specific T cell clones; (2) definition of interactions between MHC molecules and T cell receptors at the molecular level; (3) identification and elution of relevant disease inducing self-peptides complexed with MHC molecules and (4) identification of relevant genes that predispose to autoimmunity.

KW - Autoantibodies

KW - Autoimmunity

KW - Myasthenia gravis

KW - New Zealand mice

KW - Systemic lupus erythematosus

KW - T cell receptor

KW - Vaccination

UR - http://www.scopus.com/inward/record.url?scp=0026760668&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026760668&partnerID=8YFLogxK

M3 - Article

C2 - 1382742

VL - 98

SP - 181

EP - 188

JO - International Archives of Allergy and Immunology

JF - International Archives of Allergy and Immunology

SN - 1018-2438

IS - 3

ER -